However, it should be noted that this therapeutic dilemma on whether to initiate JAK inhibitors or TNF inhibitors is placed at the second step in the EULAR’s recommendations for the management of RA, as MTX remains the mainstay of initial management.11 This evidence concerns the gene TNF and rheumatoid arthritis.